Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | ATF4 | P18848 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 2/20 | 0.37 |
| ▸ | FABP2 | P12104 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459892 | 0.93 | MAP4K4 (0.57) | MAP4K4ATF4PPARAMEN1CYP1A2 | |
| SCHEMBL31117822 | 0.93 | MAP4K4 (0.61) | MAP4K4ATF4PPARAMEN1CYP1A2 | |
| SCHEMBL28585419 | 0.92 | HPGD (0.53) | MAP4K4PPARAMEN1CYP1A2CYP3A4 | |
| SCHEMBL31117904 | 0.92 | MAP4K4 (0.48) | MAP4K4ATF4PPARAMEN1CYP1A2 | |
| SCHEMBL2655299 | 0.91 | MAP4K4 (0.60) | MAP4K4ATF4PPARAMEN1CYP1A2 | |
| SCHEMBL31117784 | 0.90 | MAP4K4 (0.49) | MAP4K4ATF4MEN1KMT2AMMP13 | |
| SCHEMBL31608981 | 0.84 | MAP4K4 (0.44) | MAP4K4ATF4PPARAMEN1CYP1A2 | |
| SCHEMBL10574205 | 0.81 | HPGD (0.49) | MAP4K4ATF4MEN1KMT2AHPGD | |
| SCHEMBL19110513 | 0.81 | LDHA (0.44) | MAP4K4MEN1MAPTKMT2A | |
| SCHEMBL5323458 | 0.81 | TPMT (0.39) | MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680343-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2024192415-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-19 | — | — | WO | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2019-08-20 | — | — | US | disclosed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| CN-102405211-A | Proline derivatives as cathepsin inhibitors | HOFFMANN LA ROCHE | 2012-04-04 | — | — | CN | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | MAP4K4 3971/4885ATF4 3930/4885PPARA 3247/4885 |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | CPT1B, CLCN2, TNNC1 | MAP4K4 4558/4885ATF4 3052/4885PPARA 2774/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | MAP4K4 3971/4885ATF4 3930/4885PPARA 3247/4885 |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CPT1B, CLCN2, CACNB1 | MAP4K4 4042/4885ATF4 3176/4885PPARA 821/4885 |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | CPT1B, CLCN2, TNNC1 | MAP4K4 4558/4885ATF4 3052/4885PPARA 2774/4885 |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | MAP4K4 3971/4885ATF4 3930/4885PPARA 3247/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | MAP4K4 3971/4885ATF4 3930/4885PPARA 3247/4885 |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | MAP4K4 3971/4885ATF4 3930/4885PPARA 3247/4885 |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | MAP4K4 3971/4885ATF4 3930/4885PPARA 3247/4885 |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | MAP4K4 2414/4885ATF4 783/4885PPARA 2460/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | MAP4K4 3971/4885ATF4 3930/4885PPARA 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.